The performance of interferon gamma release assays in patients with nontuberculous mycobacterial infection: a systematic review and meta-analysis

[1] Xu D(2018)Increasing prevalence of non-tuberculous mycobacterial infection from 2004–2009 to 2012–2017: A laboratory-based surveillance in China J Infect 76 422-424

[2] Han C(2021)Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study J Infect 83 46-53

[3] Wang MS(2021)Prevalence and clinical characteristics of nontuberculous mycobacteria in patients with bronchiectasis: a systematic review and meta-analysis Respiration 100 1218-1229

[4] Wang JL(2022)expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary, Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases Lancet Infect Dis 22 178-190

[5] Tan Y(2020)Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline Eur Respir J 56 905-913

[6] Deng Y(2016)Executive Summary of the Guidelines for the Use of interferon-gamma Release Assays in the Diagnosis of Tuberculosis Infection Arch Bronconeumol 52 477-81

[7] Yan X(2015)Management of latent Mycobacterium tuberculosis infection WHO guidelines for low tuberculosis burden countries Eur Respir J 46 1563-76

[8] Liu F(2010)(2010) Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States MMWR Recomm Rep 59 1-25

[9] Tan Y(2022)Prevalence of culture-confirmed tuberculosis among patients with nontuberculous mycobacterial disease Infect Drug Resist 15 3097-3101

[10] Wang Q(2016)The performance of interferon-gamma release assay in nontuberculous mycobacterial diseases: a retrospective study in China BMC Pulm Med 16 163-112

[1] Xu D(2018)Increasing prevalence of non-tuberculous mycobacterial infection from 2004–2009 to 2012–2017: A laboratory-based surveillance in China J Infect 76 422-424

[2] Han C(2021)Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study J Infect 83 46-53

[3] Wang MS(2021)Prevalence and clinical characteristics of nontuberculous mycobacteria in patients with bronchiectasis: a systematic review and meta-analysis Respiration 100 1218-1229

[4] Wang JL(2022)expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary, Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases Lancet Infect Dis 22 178-190

[5] Tan Y(2020)Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline Eur Respir J 56 905-913

[6] Deng Y(2016)Executive Summary of the Guidelines for the Use of interferon-gamma Release Assays in the Diagnosis of Tuberculosis Infection Arch Bronconeumol 52 477-81

[7] Yan X(2015)Management of latent Mycobacterium tuberculosis infection WHO guidelines for low tuberculosis burden countries Eur Respir J 46 1563-76

[8] Liu F(2010)(2010) Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States MMWR Recomm Rep 59 1-25

[9] Tan Y(2022)Prevalence of culture-confirmed tuberculosis among patients with nontuberculous mycobacterial disease Infect Drug Resist 15 3097-3101

[10] Wang Q(2016)The performance of interferon-gamma release assay in nontuberculous mycobacterial diseases: a retrospective study in China BMC Pulm Med 16 163-112